WILMINGTON, Mass., March 27, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023. The 2023 report demonstrates Charles River’s priorities and commitments across its strategic Environmental, Social and Governance (ESG) areas of focus: Accelerate Life-Saving Therapies; Lead with Integrity; Inspire our People; and Protect our Planet.
Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.
WILMINGTON, Mass., March 21, 2024--Charles River Laboratories International, Inc. (NYSE: CRL) and National University of Singapore’s (NUS) Yong Loo Lin School of Medicine (NUS Medicine), a leading medical education institution with a world-renowned medical research field of stem cell biology and therapy, today announced a High Quality (HQ) plasmid DNA development and manufacturing agreement.